Scientific Program Day Two
Thursday | June 27, 2024
과학 프로그램 2 일 차
科学议程第一天
カンファレンス ２日目
7:00 am Coffee & Check-In
7:50 am Chair’s Opening Remarks
Identifying Novel Targets & Their Benefits to Diversify ADC Programs & Design a More Accurate ADC
8:00 am Unmet Needs in ADCs for Gastrointestinal Cancer: East-West Differences & Novel Target Strategies Beyond HER2 & TROP2
Synopsis
- Addressing the unmet needs of ADCs in gastrointestinal cancers
- Discussing the regional differences in the need for an ADC for gastrointestinal cancers
- Going beyond HER2 and TROP2: Novel targets for ADCs in gastrointestinal cancers
8:30 am Developing a Precise ADC for Novel Targets to Take Your ADC From Bench to Bedside
Synopsis
- Exploring target discovery for ADCs
- Understanding pre-clinical and clinical translation
- Developing the best-in-class ADC for precision oncology
9:00 am A Flourishing ADC space
Synopsis
- Review of the current ADC landscape, both clinical and preclinical
- Deep dive into the characteristics of ADCs in each stage of development
- Analyze trends on the recent flurry of ADC deals
9:30 am Versatile & Robust Chemical Site-Specific Conjugation Platform: AJICAP® Technology
Synopsis
- AJICAP®️ Conjugation: Examining how site-specific technologies are being employed in many of the next-generation ADCs due to the enhancement of clinically relevant biological properties observed in various preclinical studies
- AJICAP®️ Linker: Demonstrating a novel hydrophilic linker technology that enables the versatile synthesis of homogenous DAR = 1, 2, 4, 8, and higher
- Showcasing Bispecific and Trispecific antibodies produced by fully-chemical conjugation technology
10:00 am Morning Networking Break
11:00 am SGN-B6A: A Vedotin Antibody-Drug Conjugate that Targets Integrin Beta-6 & Shows Clinical Efficacy in Multiple Solid Tumor Indications
Synopsis
- Explore how sigvotatug vedotin (SV, SGN-B6A) is an investigational, first-in-class ADC, which shows high specificity towards integrin beta-6
- Overview of sigvotatug vedotin preclinical and clinical safety and efficacy data
- Discuss the rationale for clinical combination between sigvotatug vedotin and CPIs
11:30 am NN3201, a Novel C-Kit Targeting ADC, Exhibits Robust Preclinical AntiTumor Efficacy in SCLC & GIST Models
Synopsis
- Navigating the effects of NN3201 in small cell lung cancer
- Exploring a novel C-Kit targeting ADC
- Showing anti-tumor efficacy in SCLC and GIST models
Innovating Novel Linker & Payload Technologies to Increase Stability, Efficiency & Patient Treatability
12:00 pm Delivery of BET Protein Degrader to Pancreatic Cancer & Their Microenvironment Via CEACAM6-Targeted Antibody–Drug Conjugate
Synopsis
- Analyzing Antibody protein degrader conjugate
- Understanding pancreatic cancer and its effects
- Reviewing a novel payload, BET protein degrader
12:30 pm Accelerate ADC Development From DNA to BLA Through WuXi XDC’s Integrated Platform, Technology Innovation & Strong CMC Expertise
Synopsis
- Showcasing WuXi XDC’s CRDMO platform that provides comprehensive and fully integrated development and manufacturing services on all ADC components: mab intermediate, payload linker, conjugation and drug products.
- Discover how the fully integrated platform provides fastest route to IND, less than 15 months from DNA sequence to IND submission; with over 60 INDs have been successfully submitted
- Discuss how for ADCs that seek for expedited development and approval, accelerated timeline for late stage development to BLA submission is essential. With vast experience and expertise, and all-in-one manufacturing covering all ADC components, WuXi XDC provides clear path and strategy for the comprehensive efforts toward BLA
1:00 pm
Networking Lunch
Synopsis
2:00 pm Re-imagining ADCs With OmniAb’s Next-Generation Therapeutic Antibody & Alternative Scaffold Technologies
Synopsis
- Discover how OmniAb® generates naturally-optimized, fully-human custom immune repertoires in multiple host species to fit any target product profile
- Explore how they mine their repertoires using high throughput B cell discovery workflows augmented by AI-guided selections
- Highlighting their offering of a variety of antibody modalities including VH+VL, common light chain antibodies for bispecific applications, single domain (VHH) antibodies, and cow-inspired ultra-long CDR-H3 antibodies and picobodies
- Learn how OmniAb’s suite of antibody discovery capabilities are well-suited to ADCs, where on-target specificity, high affinity, developability, and versatility to fit a plethora of molecular formats are all important criteria
2:30 pm Exploring Next-Generation ADC Development From Payload & Linker Perspective to Drive ADC Performance & Innovation
Synopsis
- Explore a new Topoisomerase 1 inhibitor
- Discuss a new linker system for ADC
- Review how it had better performance than Enhertu
3:00 pm Analyzing the Advantages of Protein Homeostasis by Dual Precision Approach
Synopsis
- Discover the development of a novel, catalytic payload class
- Explore diversity of degrader SAR while also enabling conjugation
- Improve potency and selectivity of delivery to target cells
3:30 pm Afternoon Networking Break
Maximizing Therapeutic Window to Increase Efficacy & Reduce Off-Target Toxicity of Your ADC
4:00 pm PEG-Based Bispecific ADC: Better Tumor Penetration, Wider Therapeutic Window
Synopsis
- Assessing how it provides better tumor penetration
- Discussing how there were not any Fc related toxicities
- Exploring how it has a wider therapeutic window
5:00 pm Effective PK/PD Translational Strategies to Enable a Successful Early Clinical Development
Synopsis
- Defining the translational PK/PD considerations for ADC FIH starting dose prediction
- Integrating nonclinical knowledge through computational modeling and simulations to inform Phase I design dose escalations.
- Exploring translational PK/PD data to support model-informed clinical safety mitigation strategy, drug-drug interaction risks
5:30 pm Development of Selective TLR7 Agonist ADC for Tumor Localized Immunomodulation
Synopsis
- Discuss the design of a novel and selective TLR7 agonist
- Learn how Her2-TLR7a ADC activity requires Her2 and TLR7 targeting
- Explore how anti-HER2-TLR7a ADC induce robust, target dependent activation of the immune system leading to robust anti-tumor responses in vivo